Search Results - "Astruc, Beatrice"

Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist by Kaufmann, Priska, Hurst, Noémie, Astruc, Béatrice, Dingemanse, Jasper

“…Purpose The aim of this single-center, open-label study was to assess the absolute bioavailability of an oral (tablet) versus intravenous (i.v.) formulation of…”
Get full text

Modulation of Blood Pressure by Central Melanocortinergic Pathways by Greenfield, Jerry R, Miller, Jeffrey W, Keogh, Julia M, Henning, Elana, Satterwhite, Julie H, Cameron, Gregory S, Astruc, Beatrice, Mayer, John P, Brage, Soren, See, Teik Choon, Lomas, David J, O'Rahilly, Stephen, Farooqi, I. Sadaf

“…This study shows that the prevalence of hypertension in subjects carrying a loss-of-function mutation in MC4R is less than that in overweight or obese control…”
Get full text

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects by McClure, Matthew W, Berliba, Elina, Tsertsvadze, Tengiz, Streinu-Cercel, Adrian, Vijgen, Leen, Astruc, Béatrice, Patat, Alain, Westland, Christopher, Chanda, Sushmita, Zhang, Qingling, Kakuda, Thomas N, Vuong, Jennifer, Khorlin, Nick, Beigelman, Leonid, Blatt, Lawrence M, Fry, John

“…The nucleotide analog AL-335 is a pangenotypic hepatitis C virus (HCV) nonstructural protein (NS)5B inhibitor being evaluated as treatment for chronic HCV…”
Get full text

Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial by Sesay, Sanie, Brzostek, Jerzy, Meyer, Ingo, Donazzolo, Yves, Leroux-Roels, Geert, Rouzier, Régine, Astruc, Béatrice, Szymanski, Henryk, Toursarkissian, Nicole, Vandermeulen, Corinne, Kowalska, Edyta, Van Damme, Pierre, Salamand, Camille, Pepin, Stephanie

“…Here, we report a randomized multicenter phase III trial assessing the lot-to-lot consistency of the 2014-2015 Northern Hemisphere quadrivalent split-virion…”
Get full text

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip by Latreille-Barbier, Mathilde, Rouzier, Regine, Astruc, Beatrice, Lavis, Nathalie, Donazzolo, Yves

“…An inactivated split-virion trivalent influenza vaccine (IIV3; Vaxigrip®, Sanofi Pasteur) has been available globally since 1968. Here, we describe the results…”
Get full text

Long-Acting Octreotide and Prolonged-Release Lanreotide Formulations Have Different Pharmacokinetic Profiles by Astruc, Beatrice, Marbach, Peter, Bouterfa, Hakim, Denot, Caroline, Safari, Mitra, Vitaliti, Alessandra, Sheppard, Michael

“…Single‐dose pharmacokinetic (PK) profiles and multiple‐dose PK modeling were compared for long‐acting octreotide (20 or 60 mg) and prolonged‐release lanreotide…”
Get full text

Steady‐state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects by Astruc, Béatrice, Tarral, Antoine, Dostert, Philippe, Mariotti, Fabrizia, Fabbri, Laura, Imbimbo, Bruno P.

“…Aims To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CHF3381, a dual NMDA and MAO‐A inhibitor, after multiple oral doses…”
Get full text

A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial by Baldoni, Daniela, Bruderer, Shirin, Krause, Andreas, Gutierrez, Marcello, Gueret, Pierre, Astruc, Béatrice, Dingemanse, Jasper

“…Background and objectives ACT-246475 is a new reversible, selective, and potent antagonist of the platelet P2Y 12 receptor. This study was a first-in-man trial…”
Get full text

Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects by GIULIANO, Francois, KAPLAN, Steven A, CABANIS, Marie-Josée, ASTRUC, Béatrice

“…To examine the hemodynamic interactions of the phosphodiesterase type 5 (PDE-5) inhibitor tadalafil with the uroselective alpha1-blocker alfuzosin (10 mg…”
Get full text

A New Reversible and Potent P2Y^sub 12^ Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial by Baldoni, Daniela, Bruderer, Shirin, Krause, Andreas, Gutierrez, Marcello, Gueret, Pierre, Astruc, Béatrice, Dingemanse, Jasper

“…ACT-246475 is a new reversible, selective, and potent antagonist of the platelet P2Y12 receptor. This study was a first-in-man trial investigating the…”
Get full text

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip by Latreille-Barbier, Mathilde, Rouzier, Regine, Astruc, Beatrice, Lavis, Nathalie, Donazzolo, Yves

“…An inactivated split-virion trivalent influenza vaccine (IIV3; Vaxigrip®, Sanofi Pasteur) has been available globally since 1968. Here, we describe the results…”
Get full text

Hemodynamic interaction study between the alpha 1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects by Giuliano, François, Kaplan, Steven A., Cabanis, Marie-Josée, Astruc, Béatrice

“…To examine the hemodynamic interactions of the phosphodiesterase type 5 (PDE-5) inhibitor tadalafil with the uroselective alpha 1-blocker alfuzosin (10 mg…”
Get full text